IRIS
CATURANO, ALFREDO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.056
AS - Asia 2.431
NA - Nord America 2.376
SA - Sud America 360
Continente sconosciuto - Info sul continente non disponibili 136
AF - Africa 33
OC - Oceania 3
Totale 10.395
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 3.956
US - Stati Uniti d'America 2.300
SG - Singapore 748
CN - Cina 526
IT - Italia 477
VN - Vietnam 412
HK - Hong Kong 345
BR - Brasile 289
IE - Irlanda 246
KR - Corea 116
IN - India 113
DE - Germania 107
GB - Regno Unito 79
JP - Giappone 41
FR - Francia 35
CA - Canada 28
MX - Messico 27
AR - Argentina 26
NL - Olanda 22
BD - Bangladesh 20
ID - Indonesia 17
PL - Polonia 16
SE - Svezia 15
ES - Italia 13
FI - Finlandia 13
TR - Turchia 13
AT - Austria 12
CO - Colombia 12
ZA - Sudafrica 11
LT - Lituania 10
EC - Ecuador 9
UA - Ucraina 9
VE - Venezuela 8
AE - Emirati Arabi Uniti 7
IQ - Iraq 7
PK - Pakistan 7
BE - Belgio 6
CR - Costa Rica 6
CZ - Repubblica Ceca 6
EG - Egitto 6
GR - Grecia 6
IL - Israele 6
IR - Iran 6
MA - Marocco 6
PE - Perù 6
SA - Arabia Saudita 6
CH - Svizzera 4
KG - Kirghizistan 4
MY - Malesia 4
PT - Portogallo 4
RO - Romania 4
TT - Trinidad e Tobago 4
UY - Uruguay 4
AU - Australia 3
AZ - Azerbaigian 3
BO - Bolivia 3
EE - Estonia 3
JO - Giordania 3
LB - Libano 3
TW - Taiwan 3
UZ - Uzbekistan 3
BA - Bosnia-Erzegovina 2
CL - Cile 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
HN - Honduras 2
JM - Giamaica 2
LA - Repubblica Popolare Democratica del Laos 2
MO - Macao, regione amministrativa speciale della Cina 2
NP - Nepal 2
RS - Serbia 2
SI - Slovenia 2
SY - Repubblica araba siriana 2
TN - Tunisia 2
AL - Albania 1
AM - Armenia 1
AO - Angola 1
BB - Barbados 1
BG - Bulgaria 1
BH - Bahrain 1
BS - Bahamas 1
CI - Costa d'Avorio 1
CY - Cipro 1
DM - Dominica 1
DZ - Algeria 1
ET - Etiopia 1
GA - Gabon 1
GE - Georgia 1
KW - Kuwait 1
LV - Lettonia 1
MD - Moldavia 1
MU - Mauritius 1
NO - Norvegia 1
PH - Filippine 1
PR - Porto Rico 1
PS - Palestinian Territory 1
PY - Paraguay 1
QA - Qatar 1
SC - Seychelles 1
SN - Senegal 1
Totale 10.256
Salva come PNG Salva come JPEG
Città #
Moscow 1.425
San Jose 436
Singapore 373
Hong Kong 333
Dublin 231
Santa Clara 210
Ashburn 198
Council Bluffs 189
Hefei 139
Chandler 132
Ho Chi Minh City 121
Seoul 115
The Dalles 113
Naples 105
Hanoi 99
New York 80
Bengaluru 65
Beijing 50
Dallas 46
Los Angeles 45
Munich 43
Da Nang 37
São Paulo 30
Milan 26
Princeton 22
Roxbury 22
Chicago 21
Cambridge 20
Haiphong 20
Orem 19
Atlanta 18
Memphis 18
Rome 17
Falkenstein 15
Kochi 15
Tokyo 14
Bremen 13
Frankfurt am Main 13
Amsterdam 12
Hải Dương 12
Mexico City 12
Phoenix 12
Salerno 12
Caserta 11
Belo Horizonte 10
Brooklyn 10
Chennai 10
Stockholm 10
Avellino 9
Denver 9
Florence 9
Hillsboro 9
Houston 9
Biên Hòa 8
Boston 8
Des Moines 8
Istanbul 8
Montreal 8
Nuremberg 8
Warsaw 8
Bắc Ninh 7
Ercolano 7
Helsinki 7
Johannesburg 7
Liveri 7
Manchester 7
Toronto 7
Bexley 6
Brussels 6
Guarulhos 6
Lahore 6
Napoli 6
San Francisco 6
San José 6
Boardman 5
Brasília 5
Changsha 5
Curitiba 5
Damietta 5
Jacksonville 5
London 5
Mumbai 5
Nanjing 5
Nha Trang 5
Paris 5
Rio de Janeiro 5
Thanh Mỹ Tây 5
Venice 5
Vienna 5
Wroclaw 5
Afragola 4
Baghdad 4
Barranquilla 4
Brno 4
Buffalo 4
Calgary 4
Can Tho 4
Cape Town 4
Columbus 4
Duncan 4
Totale 5.311
Salva come PNG Salva come JPEG
Nome #
Cardiac Hypertrophy: from Pathophysiological Mechanisms to Heart Failure Development 205
Association between Renal Function at Admission and COVID-19 in-Hospital Mortality in Southern Italy: Findings from the Prospective Multicenter Italian COVOCA Study 194
Cardiorenal Impact of SGLT-2 Inhibitors: A Conceptual Revolution in The Management of Type 2 Diabetes, Heart Failure and Chronic Kidney Disease 169
Left bundle branch pacing and cardiac remodeling in HF patients with type 2 diabetes mellitus: epigenetic pathways and clinical outcomes 168
Effects of a Combination of Empagliflozin Plus Metformin vs. Metformin Monotherapy on NAFLD Progression in Type 2 Diabetes: The IMAGIN Pilot Study 166
ULTRASOUND TIPS IN THE LUNG CANCER DIAGNOSIS: A PILOT STUDY 164
Peripheral Neuropathy in Diabetes Mellitus: Pathogenetic Mechanisms and Diagnostic Options 161
Aspirin in a Diabetic Retinopathy Setting: insights from NO BLIND Study 159
Dysregulated Epicardial Adipose Tissue as a Risk Factor and Potential Therapeutic Target of Heart Failure with Preserved Ejection Fraction in Diabetes 159
Current Knowledge on the Pathophysiology of Lean/Normal-Weight Type 2 Diabetes 158
Coronary Microvascular Dysfunction in Diabetes Mellitus: Pathogenetic Mechanisms and Potential Therapeutic Options 158
Lack of effect on in-hospital mortality of drugs used during COVID-19 pandemic: Findings of the retrospective multicenter COVOCA study 153
Can Metformin Exert as an Active Drug on Endothelial Dysfunction in Diabetic Subjects? 153
Comment on: Effect of Vitamin D supplementation in patients with liver cirrhosis having spontaneous bacterial peritonitis: a randomized controlled study 147
The Lipid-Lowering Efficacy of a Nutraceutical Combination Including Leucoselect Phytosome, Red Yeast Rice, Policosanol and Folic Acid in Dyslipidaemia Patients: Real-World Insights 144
Cardiovascular benefits from gliflozins: Effects on endothelial function 141
Impact of liver fibrosis on COVID-19 in-hospital mortality in Southern Italy 141
Impact of Acute Kidney Injury on the COVID-19 In-Hospital Mortality in Octogenarian Patients: Insights from the COVOCA Study 140
Anti-Inflammatory and Anticancer Effects of Anticoagulant Therapy in Patients with Malignancy 140
Liver Involvement in Patients With Systemic Sclerosis: Role of Transient Elastography in the Assessment of Hepatic Fibrosis and Steatosis 139
HCC and molecular targeting therapies: Back to the future 139
Efficacy and durability of multifactorial intervention on mortality and MACEs: a randomized clinical trial in type-2 diabetic kidney disease 139
CURRENT HEPATOCELLULAR CARCINOMA SYSTEMIC PHARMACOLOGICAL TREATMENT OPTIONS 137
Alcohol Consumption and Liver Metabolism in the Era of MASLD: Integrating Nutritional and Pathophysiological Insights 136
An Update on Betrixaban, the Challenging Anticoagulant Agent for Extended Venous Thromboembolism Prophylaxis 136
The number of risk factors not at target is associated with cardiovascular risk in a type 2 diabetic population with albuminuria in primary cardiovascular prevention. Post-hoc analysis of the NID-2 trial 136
Impact of gliflozins on cardiac remodeling in patients with type 2 diabetes mellitus & reduced ejection fraction heart failure: A pilot prospective study. GLISCAR study 136
Effects of Heart Failure Therapies on Atrial Fibrillation: Biological and Clinical Perspectives 133
EFFICACY OF COVID-19 VACCINATION IN PATIENTS WITH IMMUNE SYSTEM DISORDERS AND CANCER 133
Sex-difference of multifactorial intervention on cardiovascular and mortality risk in DKD: post-hoc analysis of a randomised clinical trial 133
Comment on: Warfarin adherence and anticoagulation control in atrial fibrillation patients-a systematic review 133
Effects of Metformin in Heart Failure: From Pathophysiological Rationale to Clinical Evidence 128
Impact of chronic liver disease upon admission on COVID-19 in-hospital mortality: Findings from COVOCA study 127
Pathophysiological mechanisms and clinical evidence of relationship between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease 127
Oxidative Stress in Type 2 Diabetes: Impacts from Pathogenesis to Lifestyle Modifications 125
Non-alcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes, and Non-viral Hepatocarcinoma: Pathophysiological Mechanisms and New Therapeutic Strategies 124
Diabetic Gastroparesis: Navigating Pathophysiology and Nutritional Interventions 124
Impact of direct acting antivirals (DAAs) on cardiovascular events in HCV cohort with pre-diabetes 122
The prognostic role of interatrial block among COVID-19 patients hospitalized in medicine wards 122
Effects of metformin in heart failure: From pathophysiological rationale to clinical evidence 121
Cardiovascular Benefits from Gliflozins: Effects on Endothelial Function 120
ULTRASOUND TIPS IN THE LUNG CANCER DIAGNOSIS: A PILOT STUDY 120
The Significance of Statin-Associated Muscle Symptoms and Its Impact on Patient Adherence and Outcomes 120
Insulin resistance and cancer: molecular links and clinical perspectives 118
Modern Challenges in Type 2 Diabetes: Balancing New Medications with Multifactorial Care 118
Polypharmacy and major adverse events in atrial fibrillation 117
Optimizing Anticoagulation Management in Atrial Fibrillation: Beyond the Guidelines. How and for Whom? 116
Serum Lipids, Inflammation, and the Risk of Atrial Fibrillation: Pathophysiological Links and Clinical Evidence 112
Assessment of the Effectiveness of Ticagrelor Preloading in Mitigating Periprocedural Myocardial Injury Among Non-ST Elevation Myocardial Infarction Patients Opting for an Early Invasive Approach 112
Brugada syndrome and COVID-19 vaccines 112
Late Hepatocellular Carcinoma Occurrence in Patients Achieving Sustained Virological Response After Direct-Acting Antiviral Therapy: A Matter of Follow-Up or Something Else? 111
Long-term clinical outcomes of patients with drug-induced type 1 Brugada electrocardiographic pattern: A nationwide cohort registry study 109
The Role of Neuropathy Screening Tools in Patients Affected by Fibromyalgia 108
The Importance of Telemedicine during COVID-19 Pandemic: A Focus on Diabetic Retinopathy 107
NerveCheck master to screen patients with type 1 or type 2 diabetes for peripheral and cardiac autonomic neuropathy 106
Non-Alcoholic Fatty Liver Disease: From Pathogenesis to Clinical Impact 106
Pharmacogenomics of Cardiovascular Drugs for Atherothrombotic, Thromboembolic and Atherosclerotic Risk 105
The transition from NAFLD to MASLD: implications for Diagnosis, Prognosis, and Clinical Management 105
Mechanisms of non-alcoholic fatty liver disease in the metabolic syndrome. A narrative review 105
Predictive Value of Fatty Liver Index for Long-Term Cardiovascular Events in Patients Receiving Liver Transplantation: The COLT Study 104
Does a strict glycemic control during acute coronary syndrome play a cardioprotective effect? Pathophysiology and clinical evidence 103
Clinical Utilization and Performance of Bempedoic Acid in an Italian Real-World Setting: Insight from Campania Region 102
Commentary on Antithrombotic Effect of Protopanaxatriol Saponins from Panax notoginseng Using Zebrafish Model 102
Assessment of Response and Safety of Bulevirtide Treatment in Patients with Chronic Delta Virus Infection: The ARISTOTLE Pilot Observational Study 102
Metabolic Rewiring of Bacterial Pathogens in Response to Antibiotic Pressure—A Molecular Perspective 100
Antioxidant and Antidiabetic Potential of the Antarctic Lichen Gondwania regalis Ethanolic Extract: Metabolomic Profile and In Vitro and In Silico Evaluation 98
Insulin–Heart Axis: Bridging Physiology to Insulin Resistance 98
The Diabetic Cardiomyopathy: The Contributing Pathophysiological Mechanisms 97
Role of Albuminuria in Detecting Cardio-Renal Risk and Outcome in Diabetic Subjects 97
Clinical performance of subcutaneous vs. transvenous implantable defibrillator in patients with ischemic cardiomyopathy: data from Monaldi Rhythm Registry 96
The Diabetic Cardiomyopathy: The Contributing Pathophysiological Mechanisms 96
High HDL Cholesterol: a risk factor for Diabetic Retinopathy? Findings from NO BLIND study 94
Multidrug-Resistant Infections and Metabolic Syndrome: An Overlooked Bidirectional Relationship 93
Impact of Gliflozins on Right Heart Remodeling in Italian Patients with Type 2 Diabetes and Heart Failure: Results from the GLISCAR Real-World Study 93
Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Diabetes and Coronary Artery Disease: Translating the Benefits of the Molecular Mechanisms of Gliflozins into Clinical Practice 92
Metabolic Dysfunction-Associated Steatotic Liver Disease in Klinefelter Syndrome: High Prevalence Uncovers an Unmet Need 87
Metabolic dysfunction‐associated steatotic liver disease, insulin resistance and hepatocellular carcinoma: A deadly triad 85
Right ventricular electrocardiographic abnormalities among hospitalized COVID-19 patients: Simple marker of worst clinical outcome 84
Precision Medicine in Type 2 Diabetes Mellitus: Utility and Limitations 83
Impact of empagliflozin as add-on to metformin vs metformin continuation on MASLD progression in type 2 diabetes: The IMAGIN Study 81
Remdesivir treatment and clinical outcome in non-severe hospitalized COVID-19 patients: a propensity score matching multicenter Italian hospital experience 77
Oral Anticoagulation for Atrial Fibrillation in Octogenarians Across the Renal Function Spectrum 72
Editorial on: Canagliflozin Mediates Mitophagy Through the AMPK/PINK1/PARKIN Pathway to Alleviate Isoprenaline-Induced Cardiac Remodeling 71
The Intestinal Thread of Fate: How the Microbiota Shapes the Story of Liver Disease 68
When the dual-chamber pacing system is the optimal choice for Brugada patients in need of implantable cardiac defibrillator 62
Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects 61
Clinically recognized sepsis in older adults admitted to medical wards: patient characteristics and hospital outcomes from the REPOSI register 45
IMPACT OF EMPAGLIFLOZIN AND METFORMIN COMBINATION THERAPY VS. METFORMIN MONOTHERAPY ON MASLD PROGRESSION IN TYPE 2 DIABETES: FINDINGS FROM THE IMAGIN STUDY 13
IMPACT OF EMPAGLIFLOZIN AND METFORMIN COMBINATION THERAPY VS. METFORMIN MONOTHERAPY ON MASLD PROGRESSION IN TYPE 2 DIABETES: FINDINGS FROM THE IMAGIN STUDY 9
Old Drug, New Science: Metformin and the Future of Pharmaceutics 6
Gut Microbiota, Oxidative Stress, and Inflammation: Pathophysiological Crosstalk in MASLD, MASH, and Hepatocellular Carcinoma 6
The Genetic Landscape of Diabetes Mellitus: Lessons from Monogenic and Polygenic Forms 5
Impact of empagliflozin as add-on to metformin vs metformin continuation on MASLD progression in type 2 diabetes: The IMAGIN Study 5
Lichen-Derived Bioactive Compounds in Diabetes and Cardiovascular Risk: Experimental Evidence, Mechanisms, and Translational Challenges 5
Oxidative Stress in Diabetic Cardiomyopathy: Molecular Mechanisms and Emerging Therapeutic Targets 3
Immunometabolism in Obesity-Associated Type 2 Diabetes: Molecular Mechanisms and Emerging Therapeutic Targets 3
Totale 10.395
Salva come PNG Salva come JPEG
Categoria #
all - tutte 33.688
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 33.688
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022177 0 0 0 19 33 8 4 4 11 16 29 53
2022/2023498 28 28 15 19 67 30 5 31 230 11 10 24
2023/2024363 34 17 13 25 77 63 9 9 8 28 30 50
2024/20251.341 13 17 5 26 204 140 209 124 194 115 119 175
2025/20267.139 369 429 375 297 627 3.630 473 301 263 145 135 95
2026/2027812 40 129 479 164 0 0 0 0 0 0 0 0
Totale 10.395